hotspot -WSS

hotspot

author：knowledge 2025-08-12 11:30:17 - browse：1

David Liu and Jonathan Wosen on the STAT Summit stage. — David Liu (left) with reporter Jonathan Wosen at the 2022 STAT Summit. STAT

David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching a company focused on delivering gene-editing machinery to precise cells and tissues in the body, STAT has learned.

The company, known as Nvelop, already raised a $100 million seed round last year, according to PitchBook. It is being run by Jeff Walsh, a former top executive at Bluebird Bio, and it recently recruited Bluebird’s head of research, Melissa Bonner, according to two people with knowledge of the situation. Bluebird had not previously disclosed Bonner’s departure.

Nvelop is the latest entry in a race among top labs and deep-pocketed investors to solve a delivery problem that has stunted efforts to turn CRISPR and other genetic tools into disease-altering medicines. The goal is to develop a cargo system precise enough to deliver CRISPR or other machinery to cells of a researchers’ choosing, particularly tissues that have been hard to reach with previous approaches, like neurons, muscle, and blood stem cells.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

knowledge

WSS

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

How a scoliosis diagnosis changed the life of one young dancer

'Essentially witchcraft:' A former naturopath takes on the field

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

NIH tests clinical research in primary care with $30 million program

hotspot

hotspot

knowledge

Cancer drug shortages should be causing more outrage

How faith leaders like me can help address America's obesity epidemic

State Dept. review finds Biden bears some blame for Afghanistan failures

My daughter's legacy lives on through her writing, phage therapy

Malaria cases in Florida and Texas: Here’s what you need to know

The system is set up to fail children with medical complexity

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

New air purifier tech could be key to improving indoor air quality

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

hotspot

U.K. sequencing study surfaces new findings about tumor DNA

Pharma companies must ensure equitable access to obesity drugs

'Essentially witchcraft:' A former naturopath takes on the field

Feng Zhang CRISPR delivery startup lays off quarter of staff

J&J to buy cancer drug developer Ambrx Biopharma

Antibiotic resistance and the global rise in human conflict

hotspot

knowledge

knowledge

explore